Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Eton Pharmaceuticals, Inc.

Get SEC filing alerts via email and in your feed for Eton Pharmaceuticals, Inc.

ETON

Eton Pharmaceuticals, Inc.

About Eton Pharmaceuticals, Inc.

Eton Pharmaceuticals develops and commercializes treatments for rare diseases, offering products across endocrinology and metabolic disorders. Its portfolio includes FDA-approved drugs like INCRELEX, ALKINDI SPRINKLE, and GALZIN, with additional candidates in late-stage development. The company leverages regulatory expertise, proprietary technology, and established sales channels to serve niche patient populations worldwide. Its business model focuses on innovation, strategic acquisitions, and efficient manufacturing partnerships.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Eton Pharmaceuticals, Inc.

1
1
Eton Pharmaceuticals, Inc. Eton Pharmaceuticals Reports 40.5% Revenue Growth to $24.3 Million in Q1 2026

Via official filing (AI summary) | 20 days ago | 0 comments

2
1
Eton Pharmaceuticals, Inc. Eton Pharmaceuticals Reports $80M Revenue Growth in 2025 Fiscal Year

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Eton Pharmaceuticals, Inc. Eton Pharmaceuticals Reports $22.5 Million Revenue in Latest Quarter, Net Loss of $1.9 Million

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Eton Pharmaceuticals, Inc. Eton Pharmaceuticals Reports $18.9 Million Revenue for Q2 2025, Significant Year-Over-Year Growth

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Eton Pharmaceuticals, Inc. Eton Pharmaceuticals Reports 116% Revenue Growth to $17.3 Million in Latest Quarter

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Eton Pharmaceuticals, Inc. Eton Pharmaceuticals Reports $39M Revenue Growth and Strategic Acquisitions in 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Eton Pharmaceuticals, Inc. Eton Pharmaceuticals Reports 46.5% Revenue Growth, Net Income Turnaround in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments